We use cookies. By browsing our site you agree to our use of cookies. Accept this cookie OR Find out more

customer service software

Ocular Therapeutix Inc (OCUL) - Product Pipeline Analysis, 2018 Update

  • Published Date: 29 Aug 2018
  • Number of Pages: 33
  • Category: Company Profile
  • Country: United States of America

Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The companys products include DEXTENZA, sustained release travoprost and posterior segment injections. Its hydrogel technology uses polyethylene glycol to create ophthalmic sustained drug delivery systems. Oculars hydrogel provides containment, localization and protection from inflammatory response, and a material for sustained delivery of drugs to the eye. The company also provides ReSure Sealant, a ocular sealant proven in clinical trial to be safe in sealing clear corneal incisions following cataract surgery. Its products are used for the treatment of glaucoma and ocular hypertension, post-operative inflammation, allergic conjunctivitis, dry eye and retinal diseases. Ocular is headquartered in Bedford, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Ocular Therapeutix Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons To Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company
Publisher Name : GlobalData

List of Tables 3
List of Figures 3
Ocular Therapeutix Inc Company Overview 4
Ocular Therapeutix Inc Company Snapshot 4
Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview 4
Ocular Therapeutix Inc Pipeline Analysis Overview 7
Ocular Therapeutix Inc - Key Facts 7
Ocular Therapeutix Inc - Major Products and Services 8
Ocular Therapeutix Inc Pipeline Products by Development Stage 9
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status 11
Ocular Therapeutix Inc Pipeline Products Overview 12
DEXTENZA Product Overview 12
OTX-IVT Product Overview 13
OTX-MP Product Overview 14
OTX-TIC Product Overview 15
OTX-TIC Clinical Trial 16
OTX-TKI Product Overview 17
OTX-TP Product Overview 18
OTX-TP Clinical Trial 19
Ocular Therapeutix Inc - Key Competitors 20
Ocular Therapeutix Inc - Key Employees 21
Ocular Therapeutix Inc - Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Ocular Therapeutix Inc, Recent Developments 23
Jul 19, 2018: Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for DEXTENZA 23
Jun 29, 2018: Ocular Therapeutix Announces NDA Resubmission of DEXTENZA 23
May 03, 2018: Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular Hypertension 23
Apr 09, 2018: Ocular Therapeutix to Present Data at the American Society of Cataract and Refractive Surgery Symposium 24
Mar 08, 2018: Ocular Therapeutix Reports Fourth Quarter and Year End 2017 Financial Results and Business Update 24
Jan 08, 2018: Ocular Therapeutix Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality 26
Dec 22, 2017: Ocular Therapeutix Provides Legal Update 26
Nov 07, 2017: Ocular Therapeutix Reports Third Quarter 2017 Financial Results and Provides Corporate Update 27
Sep 25, 2017: Ocular Therapeutix Appoints Donald Notman as Chief Financial Officer 28
Sep 08, 2017: Ocular Therapeutix Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer 28
Appendix 30
Methodology 30
About GlobalData 33
Contact Us 33
Disclaimer 33

List Of Tables

Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview 4
Ocular Therapeutix Inc Pipeline Products by Equipment Type 5
Ocular Therapeutix Inc Pipeline Products by Indication 6
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status 6
Ocular Therapeutix Inc, Key Facts 7
Ocular Therapeutix Inc, Major Products and Services 8
Ocular Therapeutix Inc Number of Pipeline Products by Development Stage 9
Ocular Therapeutix Inc Pipeline Products Summary by Development Stage 10
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status 11
Ocular Therapeutix Inc Ongoing Clinical Trials Summary 11
DEXTENZA - Product Status 12
DEXTENZA - Product Description 12
OTX-IVT - Product Status 13
OTX-IVT - Product Description 13
OTX-MP - Product Status 14
OTX-MP - Product Description 14
OTX-TIC - Product Status 15
OTX-TIC - Product Description 15
OTX-TIC - To Evaluate the Safety, Efficacy, Durability, and Tolerability of OTX-TIC in Patients with Primary Open-angle Glaucoma or Ocular Hypertension 16
OTX-TKI - Product Status 17
OTX-TKI - Product Description 17
OTX-TP - Product Status 18
OTX-TP - Product Description 18
OTX-TP - Non-significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug 19
Ocular Therapeutix Inc, Key Employees 21
Ocular Therapeutix Inc, Other Locations 22
Glossary 32

List Of Figures

Ocular Therapeutix Inc Pipeline Products by Equipment Type 5
Ocular Therapeutix Inc Pipeline Products by Development Stage 9
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status 11

SpectraScience Inc (SpectraScience) is a medical device company, which undertakes the design, development, manufacture and marketing of light-based technology products. The company offers its proprietary WavSTAT Optical Biopsy System to

View Report

Laborie Medical Technologies Inc (Laborie), a subsidiary of Patricia Industries AB, develops and manufactures medical diagnostics and devices. The company offers uroflowmetry, urodynamics, pelvic floor rehabilitation and anorectal manometry products

View Report

ANGLE Plc (ANGLE) is a medical diagnostic company that offers cancer diagnostics and foetal health products. The company develops products for use in rare cell diagnostics that enable early, accurate

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports